Alkermes plc. (ALKS)
Alkermes makes prescription medicines, including LUMRYZ and LYBALVI, sold to patients through physicians and healthcare payers. It last closed at $45.45 on Nov 17, down 2.32% on the day. The average 12-month price target from 5 analysts is $57.20 (+25.9% from the last close), with a high of $68.00 and a low of $50.00. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ALKS, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $11.7M, the largest $9.3M.
Key Stats
Last 12 monthsNot reported for this period.
From ALKS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on ALKS in the past 90 days. The average target is $57.20, with a high of $68.00 and a low of $50.00, compared with the last close of $45.45.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 4 | RBC Capital | Target raised | Buy | $56 → $57 |
| Nov 4 | Wells Fargo | Target raised | Buy | $65 → $68 |
| Nov 4 | HC Wainwright & Co. | Target raised | Hold | $37 → $50 |
| Sep 24 | Goldman Sachs | Reinstated | Hold | $50 |
| Sep 22 | Baird | Target raised | Buy | $58 → $61 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 9% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 52). The nearest support is the Pivot S1 at $44.82, and the nearest resistance the 20 day average at $45.47.
| RSI (14) | 52.08 | Middle of its range | Neutral |
| MACD | 0.89 | Above its signal line | Bullish |
| Stochastic | 56.7 | Middle of its range | Neutral |
| ADX (14) | 20.1 | Weak trend | |
| Williams %R | -67.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 19.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −0.5% | Change over 10 sessions | Bearish |
| ATR (14) | $1.68 | Typical daily range, 3.7% of price |
| RSI (14) | 54.44 | Middle of its range | Neutral |
| MACD | 1.03 | Below its signal line | Bearish |
| Stochastic | 56.9 | Middle of its range | Neutral |
| ADX (14) | 28.9 | Trending up | |
| Williams %R | -47.4 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -12.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −1.1% | Change over 10 sessions | Bearish |
| ATR (14) | $3.33 | Typical daily range, 7.3% of price |
What happened before
See how ALKS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ALKS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ALKS in the last 90 days.
Dark Pool
30DALKS Institutional Ownership
Full report →- ●205 buying vs 188 selling
- ▼Held by funds -1.8 pts
- ▼Funds holding -12
- ▲Superinvestors: 3 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 415 | 427 | −2.8% |
| In funds' top 10 | 9 | 11 | −18.2% |
| Held by funds | 104.2% | 106.0% | −1.8 pts |
| New / increased | 48 / 157 | 87 / 137 | −8.5% |
| Reduced / sold out | 129 / 59 | 137 / 52 | −0.5% |
| Put/call ratio | 0.51 | 0.03 | +1774.6% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALKS is in one of them and how their past ALKS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALKS in an article yet. Here's the latest on the wider market.
ALKS Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Sep 29, 2026 | Oct 12, 2026 | 13 d |
| Donald J TrumpExecutive branch | Sell | $50K – $100K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Gilbert CisnerosD · CA | Buy | $15K – $50K | Jul 30, 2026 | Sep 4, 2026 | 36 d |
| Donald J TrumpExecutive branch | Sell | $1K – $15K | May 15, 2026 | Jul 1, 2026 | 47 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Alkermes
Alkermes is a pharmaceutical company based in Dublin, Ireland, that makes prescription medicines. Its products include LUMRYZ and LYBALVI, which are sold in the U.S. and in markets outside the U.S. Physicians prescribe these products to patients, and sales depend on coverage and reimbursement from government programs, private insurers and pharmacy benefit managers. Pricing and coverage decisions by these payers affect how much revenue the company earns from its products.
- Headquarters
- Dublin 4, Ireland




